
Astrazeneca Pharma India (ASTRAZEN) Share Price Near 52-Week Low as Stock Trades at Rs 5,866
Updated: 8 Oct 2026 • 10:24 am
Posted by:

Astrazeneca Pharma India Ltd Share Price is trading at Rs 5,866, down 0.89% on the day, and remains close to its 52-week low while the company’s market capitalisation stands at Rs 14,796.38 crore. Astrazeneca Pharma India Share Price Today is drawing attention because the stock opened at Rs 5,918.60, touched a high of Rs 5,918.60 and a low of Rs 5,866, while the latest Univest data confirms the price event but does not establish a company-specific catalyst. Astrazeneca Pharma India Share Price News is therefore centred on price action, valuation and market positioning rather than a verified trigger. In the current Astrazeneca Pharma India Stock News flow, Univest data points to weak momentum, a premium valuation and a sharp distance from key long-term moving averages. Investors tracking Astrazeneca Pharma India Share Price Today should watch whether the stock stabilises near support or extends its one-year low pressure.
Astrazeneca Pharma India Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 5,866 |
| Previous Close | Rs 5,918.55 |
| Today's Move | Rs -52.55 (-0.89%) |
| Open | Rs 5,918.6 |
| High | Rs 5,918.6 |
| Low | Rs 5,866 |
| Market Capitalisation | Rs 14,796.38 crore |
Astrazeneca Pharma India Ltd. (ASTRAZEN) traded at Rs 5,866 versus the previous close of Rs 5,918.55, a fall of 0.89%. The stock opened at Rs 5,918.6, reached a high of Rs 5,918.6, touched a low of Rs 5,866.
Astrazeneca Pharma India Share Price Today shows a modest intraday decline from the previous close of Rs 5,918.55 to Rs 5,866, a fall of Rs 52.55 or 0.89%. The stock opened at Rs 5,918.60, matched the day’s high at Rs 5,918.60, and then moved down to Rs 5,866, which also stands as the day’s low. That price path indicates immediate selling pressure after the open, with Astrazeneca Pharma India Share Price holding close to the lower end of the day’s range. With market capitalisation at Rs 14,796.38 crore, Astrazeneca Pharma India Share Price News remains relevant for traders who monitor price action, support and one-year low levels. The current move keeps Astrazeneca Pharma India Share Price within the 52-week low discussion, and the next question is whether the stock can base near this zone or stay under pressure on Share Market Today.
Astrazeneca Pharma India Ltd. (ASTRAZEN) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 14,796.38 crore |
| P/E Ratio | 87.23x |
| P/B Ratio | 16.36x |
| ROE | 23.02% |
| ROCE | 31.24% |
| EPS | Rs 67.85 |
| Book Value Per Share | Rs 361.68 |
| Dividend Yield | 0.61% |
Astrazeneca Pharma India Ltd. (ASTRAZEN) fundamental metrics show P/E 87.23x, P/B 16.36x, ROE 23.02%, ROCE 31.24%. These figures provide context only and are not a buy or sell signal.
Astrazeneca Pharma India Ltd. has a market capitalisation of Rs 14,796.38 crore, which gives readers a sense of company size before judging valuation. On valuation, P/E at 87.23x, P/B at 16.36x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 23.02% and ROCE of 31.24%, helping investors compare shareholder returns and capital efficiency. According to latest Univest data, additional metrics include EPS of Rs 67.85, book value per share of Rs 361.68, dividend yield of 0.61%, adding context to earnings, balance-sheet value and historical payout. Against the latest Univest same industry benchmark, these figures can be compared with benchmark median P/E of 27.91x, median ROE of 11.48%, median ROCE of 13.28%. These numbers explain the fundamental backdrop without converting the article into a buy or sell view.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 87.23x |
| Benchmark Median P/E | 27.91x |
| Benchmark Average P/E | 40.94x |
| Benchmark P/E Range | 0x to 708.87x |
| Company P/B Ratio | 16.36x |
| Benchmark Median P/B | 2.81x |
| Company ROE | 23.02% |
| Benchmark Median ROE | 11.48% |
| Company ROCE | 31.24% |
| Benchmark Median ROCE | 13.28% |
| Company Market Capitalisation | Rs 14,796.38 crore |
| Benchmark Median Market Cap | Rs 828.13 crore |
Astrazeneca Pharma India Ltd. (ASTRAZEN) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.
Astrazeneca Pharma India Ltd. (ASTRAZEN) has a P/E ratio of 87.23x, which is above the benchmark median of 27.91x, a difference of +212.54%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.
Astrazeneca Pharma India Ltd. (ASTRAZEN) has a ROE of 23.02%, which is above the benchmark median of 11.48%, a difference of +100.52%. Astrazeneca Pharma India Ltd. (ASTRAZEN) has a ROCE of 31.24%, which is above the benchmark median of 13.28%, a difference of +135.24%.
Track stocks falling to yearly lows through the Univest 52-week-low screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Marksans Pharma Ltd. | MARKSANS | 14,698.37 | 28.53 | 4.64 | 15.31 | 21.1 |
| Concord Biotech Ltd. | CONCORDBIO | 14,306.79 | 51.56 | 6.85 | 13.54 | 18.04 |
| Jubilant Pharmova Ltd. | JUBLPHARMA | 15,737.77 | 44.07 | 2.18 | 5.97 | 8.69 |
| Natco Pharma Ltd. | NATCOPHARM | 16,158.35 | 13.89 | 1.7 | 16.3 | 17.16 |
| Alembic Pharmaceuticals Ltd. | APLLTD | 16,391.4 | 23.61 | 2.8 | 12.35 | 11.74 |
Astrazeneca Pharma India Ltd. (ASTRAZEN) has a P/E ratio of 87.23x compared with the displayed peer median of 28.53x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 23.02% compares with a peer median of 13.54% across the companies shown in the table. ROCE stood at 31.24% versus the displayed peer median of 17.16%, providing a capital-efficiency comparison. Astrazeneca Pharma India Ltd. (ASTRAZEN) has a market capitalisation of Rs 14,796.38 crore. Among the 5 peers shown, 3 have a larger market capitalisation.
Why Investors Are Watching Astrazeneca Pharma India
- Astrazeneca Pharma India Share Price is trading near its 52-week low, keeping price action in focus.
- RSI at 17.75 shows weak momentum and deep oversold conditions in Astrazeneca Pharma India Share Price Today.
- The stock trades below the 50-day and 200-day moving averages, which keeps the trend under pressure.
- Valuation remains elevated, with Astrazeneca Pharma India Fundamental Analysis showing a high P/E and P/B.
- ROE of 23.02% and ROCE of 31.24% show strong return metrics despite the weak share price.
About Astrazeneca Pharma India
Astrazeneca Pharma India Ltd. operates in the Pharmaceuticals & Drugs industry within the Healthcare sector. Astrazeneca Pharma India Share Price reflects the market’s view of a company whose reported financial ratios show strong profitability and premium valuation. The latest quarter revenue of Rs 682.79 crore for Jun 2026 gives a recent operating reference point for Astrazeneca Pharma India Company News and Astrazeneca Pharma India Stock Performance. The company’s market cap of Rs 14,796.38 crore places it in the mid-to-large bracket within its industry set. Investors often track Astrazeneca Pharma India Share Price Today alongside company financials, earnings quality, book value and return ratios because the stock trades at a notable premium to the industry norm. In Univest coverage, Astrazeneca Pharma India Stock News is best understood through a combination of price behaviour, valuation and sector-relative profitability.
Track Astrazeneca Pharma India Share Price on Univest
Use Astrazeneca Pharma India Ltd. (ASTRAZEN) live share-price page, Univest 52-week-low screener, Univest market blogs to review live stock data, yearly-low lists and related market analysis.
Track Astrazeneca Pharma India Share Price on Univest to follow live price updates, technical indicators, fundamental ratios, shareholding pattern, 52-week levels and market insights in one place. Univest helps readers monitor Astrazeneca Pharma India Share Price Today with a clear view of stock analysis, sector context and company financials.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Uniresearch Global Pvt. Ltd. (Research Analyst, SEBI Registration Number INH000013776), a subsidiary of Univest Communication Technologies Private Limited.
Frequently Asked Questions
Why is Astrazeneca Pharma India Share Price falling today?
Ans. Astrazeneca Pharma India Share Price is down 0.89% to Rs 5,866. Univest data confirms weak price action near a 52-week low, but it does not establish a company-specific catalyst for the move.
What is Astrazeneca Pharma India Share Price today?
Ans. Astrazeneca Pharma India Share Price today is Rs 5,866, compared with the previous close of Rs 5,918.55. The stock opened at Rs 5,918.60 and moved lower during the morning session.
Is Astrazeneca Pharma India near its 52-week low?
Ans. Yes. Astrazeneca Pharma India Share Price is trading close to its 52-week low, which is why it is drawing attention as a stocks in news name on Stock Market Today.
How does Astrazeneca Pharma India compare with its sector benchmark?
Ans. Astrazeneca Pharma India Share Price trades at a P/E of 87.23 versus the industry median of 27.91 and an average of 40.94. Its ROE and ROCE are both above the benchmark.
Is Astrazeneca Pharma India expensive on valuation?
Ans. Astrazeneca Pharma India Share Price looks higher-valued versus the healthcare benchmark on both P/E and P/B. However, the company’s higher ROE and ROCE show strong return generation against that valuation.
How does Astrazeneca Pharma India compare with peers?
Ans. Astrazeneca Pharma India Share Price has a market cap close to Marksans Pharma and Concord Biotech, but its P/B is much higher than most listed peers in the comparison set.
What should investors watch next in Astrazeneca Pharma India Share Price?
Ans. Investors should watch whether Astrazeneca Pharma India Share Price stays near support, remains below the 50-day and 200-day moving averages, and holds its current trend around the yearly low zone.
What do ROE and ROCE show for Astrazeneca Pharma India?
Ans. Astrazeneca Pharma India Share Price is backed by ROE of 23.02% and ROCE of 31.24%. Those numbers indicate strong capital efficiency even though the stock price is weak. ROE stands at 23.02%.
Should investors track Astrazeneca Pharma India Share Price on Univest?
Ans. Yes. Univest tracks Astrazeneca Pharma India Share Price Today with live updates, technical indicators, valuation ratios and shareholding pattern so investors can monitor the stock’s near-52-week-low setup. The stock moved -0.89% during the session.
Recent Articles

Stocks to Buy for 2027: Ventura's Samvat 2083 Picks Include HDFC Bank, Paytm, Meesho, Ather, LG Electronics India and Park Medi World, With Targets Up to 75% Above the Price at Publication
13 November 2026

Microsoft Outage on 13 November 2026 Sends Traders Back to Phones and Fax: What the Outlook, Teams and Copilot Failure Means for Global Markets, Indian Brokerages and Investors
13 November 2026

Ingersoll Rand Dividend of Rs 20 Per Share: Record Date 19 November 2026, Payout on 2 December and What the Q2 FY27 Profit Rise of 9% Says About the Payout and the Stock
13 November 2026

Viceroy Hotels Share Price Gains Nearly 4% After Q2 FY27 Results: Revenue Up 56.5% to Rs 48.20 Crore but Profit Halves to Rs 2.23 Crore, and Why the Rs 106 Crore Rights Issue Matters on 13 November 2026
13 November 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
Stocks to Buy for 2027: Ventura's Samvat 2083 Picks Include HDFC Bank, Paytm, Meesho, Ather, LG Electronics India and Park Medi World, With Targets Up to 75% Above the Price at Publication
Microsoft Outage on 13 November 2026 Sends Traders Back to Phones and Fax: What the Outlook, Teams and Copilot Failure Means for Global Markets, Indian Brokerages and Investors
Ingersoll Rand Dividend of Rs 20 Per Share: Record Date 19 November 2026, Payout on 2 December and What the Q2 FY27 Profit Rise of 9% Says About the Payout and the Stock
Viceroy Hotels Share Price Gains Nearly 4% After Q2 FY27 Results: Revenue Up 56.5% to Rs 48.20 Crore but Profit Halves to Rs 2.23 Crore, and Why the Rs 106 Crore Rights Issue Matters on 13 November 2026
SC Agrotech Bonus Issue and Stock Split: 4:5 Bonus and 1:10 Split Proposed as the Stock Locks a 5% Upper Circuit at Rs 62.38, Q2 Profit Up 48 Times and What Shareholders Should Check Before the 11 December EGM

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times





